Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity—myocarditis and pericarditis—are k...

Full description

Bibliographic Details
Main Authors: Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Jun Matsumoto, Toshihiko Yoshioka, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Drug Safety and Regulation
Subjects:
atezolizumab
bevacizumab
cardiovascular toxicity
thromboembolism
adverse event
Online Access:https://www.frontiersin.org/articles/10.3389/fdsfr.2023.1213771/full

Internet

https://www.frontiersin.org/articles/10.3389/fdsfr.2023.1213771/full

Similar Items